Evaluation of Levetiracetam as Adjunctive Treatment for Refractory Canine Epilepsy: A Randomized, Placebo‐Controlled, Crossover Trial

Journal of Veterinary Internal Medicine

K.R. Muñana¹  W.B. Thomas²  K.D. Inzana³  J.A. Nettifee-Osborne¹  K.J. McLucas²  N.J. Olby¹  C.J. Mariani¹ 

[1] Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC;Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN;Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA

关键词: Clinical pharmacology;    CNS disorders;    Dog;    Epilepsy;    Neurology;    Seizures;   

DOI  :  10.1111/j.1939-1676.2011.00866.x

来源: Wiley

【 摘 要 】

Abstract

Background

There is little evidence-based information available to guide treatment of refractory epilepsy in dogs. The antiepileptic drug levetiracetam (LEV) is administered to dogs, although its safety and efficacy are unknown.

Objective

To evaluate the safety and efficacy of LEV as adjunctive therapy for refractory epilepsy in dogs.

Animals

Thirty-four client-owned dogs with idiopathic epilepsy.

Methods

Randomized, blinded trial involving dogs resistant to phenobarbital and bromide. Dogs received LEV (20 mg/kg PO q8h) or placebo for 16 weeks, and after a 4-week washout were crossed over to the alternate treatment for 16 weeks. Owners kept records on seizure frequency and adverse events. Hemogram, chemistry profile, urinalysis, and serum antiepileptic drug concentrations were evaluated at established intervals.

Results

Twenty-two (65%) dogs completed the study. Weekly seizure frequency during the 1st treatment period decreased significantly during LEV administration relative to baseline (1.9 ± 1.9 to 1.1 ± 1.3, P = .015). The reduction in seizures with LEV was not significant when compared to placebo (1.1 ± 1.3 versus 1.5 ± 1.7, P = .310). The most common adverse event was ataxia, with no difference in incidence between LEV and placebo (45 versus 18%, P = .090). No changes in laboratory parameters were identified and owners reported an improved quality of life (QOL) with LEV compared to placebo (QOL score 32.7 ± 4.3 versus 29.4 ± 4.5, P = .028).

Conclusions and Clinical Importance

Adjunctive treatment with LEV appears safe in epileptic dogs. Efficacy of LEV over placebo was not demonstrated, although the power of the study was limited. Further evaluation of LEV as treatment for epilepsy in dogs is warranted.

【 授权许可】

Unknown   
Copyright © 2012 by the American College of Veterinary Internal Medicine